.
MergerLinks Header Logo

Announced

Shoreline Biosciences to acquire the iNK cell franchise and gene editing technologies of Editas Medicine.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Acquisition

Single Bidder

Biotechnology

Friendly

United States

Private

genome editing

Majority

Pending

Domestic

Synopsis

Edit

Shoreline Biosciences, a genome editing company, agreed to acquire the iNK cell franchise and gene editing technologies of Editas Medicine, a biotechnology company. Financial terms were not disclosed. “The acquisition of our allogeneic iNK franchise by Shoreline is highly aligned with our strategic portfolio reprioritization, as it allows us to sharpen our efforts on advancing current clinical stage trials and focus our resources on in vivo fit-for-purpose therapeutic construction and development. Shoreline is a leader in developing next generation iNK and macrophage cell therapies, and we believe they are the right company to move these assets toward clinical applications," Gilmore O’Neill, Editas Medicine President and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US